Clinical Trials
20 trialsNCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04379518 2026-01-13
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT02712905 2025-11-04
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02849886 2025-07-09
Side_by_Cide
Centre Hospitalier Universitaire de Besancon
Phase 1/2 Terminated
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT04735575 2025-05-28
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03648372 2024-11-19
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
Phase 1/2 Terminated
NCT02091063 2024-08-06
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT02361346 2022-08-18
MT-3724NHL001
Molecular Templates, Inc.
Phase 1/2 Terminated
NCT03875495 2022-01-28
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Genenta Science
Phase 1/2 Terminated
NCT03605212 2021-06-03
FLORET
Menarini Group
Phase 1/2 Terminated
NCT02431260 2019-06-14
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT00058825 2016-11-07
HIMSUM
Baylor College of Medicine
Phase 1/2 Terminated
NCT00838890 2015-10-12
A Study of BMS-863233 in Patients With Hematologic Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00499239 2014-02-04
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Gilead Sciences
Phase 1/2 Terminated
NCT00424645 2012-12-06
Voraxaze for Delayed Methotrexate Clearance
M.D. Anderson Cancer Center
Phase 1/2 Terminated